The group reckons big pharma is eyeing KIF18A inhibition, but for now there are just a handful of players.

Blockade of CCR8 has quietly emerged as a hot oncology target, especially for anti-PD-(L)1 MAb combinations.

The company is setting up another battle with Bristol Myers Squibb, while Amgen has different plans.

Genmab’s remarkably bold acquisition raises more questions about Sutro, a key FRα rival of ProfoundBio.

A roundup of the first quarter's key oncology drug approvals and rejections.

The takeover of AnHeart centres on advancing the latter’s targeted lung cancer project taletrectinib.

Checkmate-9DW scores a topline win on overall survival, when failure seemed more likely.